BRAF and neoplasm: While monotherapy with the BRAFi vemurafenib or the MEKi trametinib showed no anti-tumor effects in BRAF-mutant xenograft models, the combination of the MCL-1i AZD5991 with these inhibitors reduced tumor growth [70].